EVGN רווח נקי למניה ב-12 החודשים האחרונים Evogene Ltd

Expanding influence in the computational biology segment via AI creates a robust patent barrier for Evogene Ltd. (EVGN). The 12-month rolling specific income metric visualizes this growth, where the parameter value reaches -0.91. Success is based on scientific authority in genome optimization, while capitalization relies on the licensing of innovative seeds and pharmaceuticals developed through DNA analysis.

Evogene Ltd. specializes in developing AI bioanalysis systems through strategic partnerships and licensing. TTM earnings per share measures the final income attributable to a single share over a year, reflecting the actual efficiency of capital management. By analyzing TTM earnings per share dynamics, an investor assesses management's ability to convert collaborations into financial margins. Stagnation of this metric amid low trading volume signals risks of a sharp drawdown, while steady growth of the metric confirms the fundamental resilience of the business model.